Pretreatment pregnancy testing under iPLEDGE, the safety program for isotretinoin, still requires clinic or laboratory testing in 2026. Home testing is now allowed during and after treatment, with implementation due Aug. 9, 2026, as described in Drugs.com reporting on the FDA action.
Isotretinoin treats severe recalcitrant nodular acne that has not improved with conventional therapy. The same rules cover adults with persistent acne who meet that definition. Timing matters because the pretreatment sequence controls when you can start.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What must happen before the first dose?
- What is easier during and after treatment?
- Who do these rules affect?
- What should you do before Aug. 9, 2026?
What must happen before the first dose?
Patients who can become pregnant still need two negative pretreatment tests. The first screening test starts a 30-day wait before the second test and prescription, according to the FDA contraception counseling guide. Both pretreatment tests must occur in a medical setting such as a prescriber office, clinic, or laboratory, stated in the FDA medical organizations letter.
Home kits cannot replace this first sequence. Ask your prescriber how the 30-day dates are counted for your case. Confirm where each test will occur before you leave the first visit.
- Complete the first screening test at the office, clinic, or lab.
- Wait 30 days, then return for the second confirmatory test.
- Obtain the prescription after the second negative result.
What is easier during and after treatment?
Prescribers may now let patients who can become pregnant test at home during and after treatment. This replaces clinic-only testing for that phase, as summarized in the National Community Pharmacists Association summary. Dermatology Advisor reporting notes FDA removed the CLIA-certified laboratory requirement.
The medical-setting rule still applies to pretreatment tests. The Journal of Dermatology for NPs/PAs reports FDA ended the 19-day lockout after a missed 7-day prescription window. A patient can now complete an immediate repeat test without added waiting.
Who do these rules affect?
These rules cover isotretinoin for severe recalcitrant nodular acne in nonpregnant patients age 12 and older, according to the DailyMed label. That use is limited to acne unresponsive to conventional therapy.
An adult with deep, persistent nodules despite antibiotics or retinoids may fall in this group. An adult with mild clogged pores cleared by standard care does not. Ask your dermatologist whether your history meets the definition.
What should you do before Aug. 9, 2026?
The Journal of Dermatology for NPs/PAs reports FDA is allowing enforcement discretion until Aug. 9, 2026. During that period, reported home tests and non-CLIA tests may be used during and after treatment, which supports telehealth follow-up.
The same journal summary states clinics must set procedures for accurate documentation and reduced falsification risk. Expect clear instructions on how to document and report each result. If you plan to start soon, book pretreatment visits first and confirm home-test rules for later months. Bring your contraception history and testing questions to the first appointment.
You Might Also Like
- Planned Home Pregnancy Testing Under the 2026 iPLEDGE Changes: What Changed, What Did Not, and What Comes Next for Adult Acne Patients
- Pretreatment Pregnancy Testing Under iPLEDGE in 2026: Pharmacy and Prescriber Questions for Adult Acne Patients
- Planned Home Pregnancy Testing Under the 2026 iPLEDGE Changes: Pharmacy and Prescriber Questions for Adult Acne Patients